Identifying novel transcript biomarkers for hepatocellular carcinoma (HCC) using RNA-Seq datasets and machine learning.
Source check: Source checked. Not independent scientific confirmation.
Finding: Primary BMC Cancer Methods/Results used RNA-seq from 33 HCC cell models and machine-learning feature selection to nominate PARP2-202, SPON2-203 and CYREN-211; the work expressly has no patient or independent experimental biomarker validation. Approve only as a bounded cell-model transcript-discrimination result, not as clinically established biomarkers.
Technology: SVM/RFE and other classifiers select transcript features from HCC-vs-healthy cell-model RNA-seq; use of ML is explicit in Methods.
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
- AI contribution
- SVM/RFE and other classifiers select transcript features from HCC-vs-healthy cell-model RNA-seq; use of ML is explicit in Methods.
- Test and result
- Three transcripts discriminate HCC and healthy liver cell models in repeated cross-validation; paper reports the candidate signatures as putative biomarkers and explains the single-replicate limits.
- Limitation / still unknown
- Cross-validation and random transcript comparisons are internal model checks, not patient validation; exact narrow claim limited to cell models.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://link.springer.com/article/10.1186/s12885-021-08704-9 · https://pubmed.ncbi.nlm.nih.gov/34445986/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 2/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.